SCHEMBL15914064

SCHEMBL15914064

O=C(O)C1CCC(c2onc3c2CCCC3)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.39
TP53 P04637 5/20 0.39
DHODH Q02127 1/20 0.35
THRB P10828 1/20 0.35
RAB9A P51151 7/20 0.34
NPC1 O15118 6/20 0.34
PKM P14618 3/20 0.34
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTT P42858 1/20 0.34
MAPT P10636 2/20 0.33
POLB P06746 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
RORC P51449 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
ALDH1A1 P00352 2/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14853198 1.00 SMN1; SMN2 (0.39) SMN1; SMN2TP53DHODHTHRBRAB9A
SCHEMBL2579226 0.83 MAPT (0.39) SMN1; SMN2TP53DHODHTHRBRAB9A
SCHEMBL2579228 0.83 MAPT (0.39) SMN1; SMN2TP53DHODHTHRBRAB9A
SCHEMBL2586411 0.83 SMN1; SMN2 (0.40) SMN1; SMN2TP53DHODHTHRBRAB9A
SCHEMBL2586413 0.83 SMN1; SMN2 (0.40) SMN1; SMN2TP53DHODHTHRBRAB9A
SCHEMBL14844238 0.75 SMN1; SMN2 (0.38) SMN1; SMN2TP53THRBRAB9ANPC1
SCHEMBL2579232 0.73 SMN1; SMN2 (0.43) SMN1; SMN2TP53DHODHRAB9ANPC1
SCHEMBL2579749 0.73 SMN1; SMN2 (0.43) SMN1; SMN2TP53DHODHRAB9ANPC1
SCHEMBL2582653 0.70 SMN1; SMN2 (0.40) SMN1; SMN2TP53DHODHRAB9ANPC1
SCHEMBL2582656 0.70 SMN1; SMN2 (0.40) SMN1; SMN2TP53DHODHRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763997-B1 CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS HOFFMANN LA ROCHE (CH) 2017-08-02 EP disclosed
US-9346824-B2 Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists HOFFMAN-LA ROCHE, INC. (US) 2016-05-24 US disclosed
US-20140221350-A1 Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists HOFFMANN-LA ROCHE INC. (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221350-A1 Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists AVPR1A, AVPR1B, OXTR SMN1; SMN2 2648/4885TP53 3456/4885DHODH 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.